Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT01576172
Show Display Options
Rank Status Study
1 Active, not recruiting Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Drug: Abiraterone Acetate;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Drug: Veliparib

Study has passed its completion date and status has not been verified in more than two years.